NVIVQ — InVivo Therapeutics Holdings Share Price
Last trade - 00:00- $1.22m
- -$7.36m
- 13
- 57
- 20
- 20
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.13 | ||
| Price to Tang. Book | 0.13 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -110.52% | ||
| Return on Equity | -98.11% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries (SCIs). The Company's Neuro-Spinal Scaffold implant is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. It is intended to promote appositional, or side-by-side, healing by supporting the surrounding tissue after injury, minimizing the expansion of areas of necrosis, and providing a biomaterial substrate for the body's own healing/repair processes following injury. It is composed of two biocompatible and bioresorbable polymers that are cast to form a porous investigational product: Poly lactic-co-glycolic acid and Poly-L-Lysine. Poly lactic-co-glycolic acid is a polymer that is used in resorbable sutures and provides biocompatible support for Neuro-Spinal Scaffold implants and Poly-L-Lysine is a positively charged polymer used to coat surfaces.
Directors
- C. Ann Merrifield NEC (70)
- Richard Toselli PRE (63)
- Richard Christopher CFO (51)
- Daniel Marshak IND (63)
- Christina Morrison IND (54)
- Richard Roberts IND (77)
- Robert Rosenthal IND (64)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- April 2nd, 2003
- Public Since
- November 14th, 2006
- No. of Shareholders
- 260
- No. of Employees
- 6
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 3,105,446
- Address
- Building 1400 East 4Th Floor, CAMBRIDGE, 02139
- Web
- https://www.invivotherapeutics.com/
- Phone
- +1 6178635524
- Auditors
- RSM US LLP
Upcoming Events for NVIVQ
Similar to NVIVQ
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
Acutus Medical
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
FAQ
As of Today at 21:24 UTC, shares in InVivo Therapeutics Holdings are trading at $0.38. This share price information is delayed by 15 minutes.
Shares in InVivo Therapeutics Holdings last closed at $0.38 and the price had moved by -70.99% over the past 365 days. In terms of relative price strength the InVivo Therapeutics Holdings share price has underperformed the S&P500 Index by -75.65% over the past year.
The overall consensus recommendation for InVivo Therapeutics Holdings is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
InVivo Therapeutics Holdings does not currently pay a dividend.
InVivo Therapeutics Holdings does not currently pay a dividend.
InVivo Therapeutics Holdings does not currently pay a dividend.
To buy shares in InVivo Therapeutics Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.38, shares in InVivo Therapeutics Holdings had a market capitalisation of $1.18m.
Here are the trading details for InVivo Therapeutics Holdings:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NVIVQ
Based on an overall assessment of its quality, value and momentum InVivo Therapeutics Holdings is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like InVivo Therapeutics Holdings. Over the past six months, its share price has underperformed the S&P500 Index by -53.59%.
As of the last closing price of $0.38, shares in InVivo Therapeutics Holdings were trading -38.75% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The InVivo Therapeutics Holdings PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.38.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
InVivo Therapeutics Holdings' management team is headed by:
- C. Ann Merrifield - NEC
- Richard Toselli - PRE
- Richard Christopher - CFO
- Daniel Marshak - IND
- Christina Morrison - IND
- Richard Roberts - IND
- Robert Rosenthal - IND